Insight & Intelligence

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

July 01, 2008 (Vol. 28, No. 13)

Quantifying Downstream Capacity Crunch

Column Resins Are Implicated by Many Experts As the Source of Biomanufacturing's Woes

  • In today’s biomanufacturing environment, downstream capacity has become a partial roadblock to nearly all CMOs (94%) and more than half (61%) of biotherapeutic developers. Extensive data from 434 biopharmaceutical manufacturers in 32 countries is summarized in BioPlan Associates’ just-released 5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.